Aviva PLC Madrigal Pharmaceuticals, Inc. Transaction History

Aviva PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 10, 2021	SELL	$97.2 - $137.59 $1.02 Million - $1.44 Million	-10,495 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$108.54 - $125.2 $38,531 - $44,446	355 Added 3.5%	10,495 $1.23 Million
Q4 2020 Feb 10, 2021	SELL	$110.06 - $133.7 $904,583 - $1.1 Million	-8,219 Reduced 44.77%	10,140 $1.13 Million
Q3 2020 Nov 12, 2020	SELL	$99.78 - $124.21 $386,248 - $480,816	-3,871 Reduced 17.41%	18,359 $2.18 Million
Q2 2020 Aug 13, 2020	SELL	$60.13 - $125.71 $1.78 Million - $3.73 Million	-29,642 Reduced 57.14%	22,230 $2.52 Million
Q1 2020 May 14, 2020	BUY	$66.76 - $93.49 $2.18 Million - $3.06 Million	32,721 Added 170.86%	51,872 $3.46 Million
Q4 2019 Feb 10, 2020	BUY	$84.28 - $118.5 $1.61 Million - $2.27 Million	19,151 New	19,151 $1.75 Million

296

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.8B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

Stay updated on Aviva PLC with notifications on news.